HealthEquity, Inc. (NASDAQ:HQY) Shares Purchased by State Street Corp

State Street Corp grew its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 0.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,131,900 shares of the company's stock after buying an additional 23,613 shares during the quarter. State Street Corp owned 3.59% of HealthEquity worth $256,346,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of HQY. Wasatch Advisors LP grew its stake in shares of HealthEquity by 6.6% in the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company's stock worth $635,065,000 after acquiring an additional 483,269 shares in the last quarter. Clearbridge Investments LLC grew its stake in HealthEquity by 1.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company's stock worth $204,915,000 after purchasing an additional 43,491 shares in the last quarter. Mackenzie Financial Corp increased its holdings in HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company's stock worth $203,822,000 after purchasing an additional 325,906 shares during the period. Dimensional Fund Advisors LP raised its position in HealthEquity by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,547,402 shares of the company's stock valued at $133,377,000 after purchasing an additional 115,841 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of HealthEquity by 2.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company's stock valued at $92,216,000 after buying an additional 24,665 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.

Insider Buying and Selling at HealthEquity

In related news, Director Frank Corvino sold 1,039 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now owns 3,784 shares of the company's stock, valued at $363,642.40. This trade represents a 21.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,536 shares of company stock worth $884,517. 2.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on HQY. The Goldman Sachs Group initiated coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a "neutral" rating and a $108.00 price objective for the company. BTIG Research upped their price objective on HealthEquity from $110.00 to $130.00 and gave the stock a "buy" rating in a research report on Thursday, November 14th. JMP Securities raised their target price on HealthEquity from $105.00 to $107.00 and gave the stock a "market outperform" rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft upped their price target on HealthEquity from $102.00 to $103.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. Finally, Mizuho started coverage on shares of HealthEquity in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 price target on the stock. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, HealthEquity presently has an average rating of "Moderate Buy" and a consensus target price of $110.71.

HealthEquity Price Performance

HQY traded up $1.97 on Wednesday, hitting $97.36. 851,121 shares of the company were exchanged, compared to its average volume of 634,217. The business's fifty day moving average is $93.11 and its 200 day moving average is $83.90. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $105.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The firm has a market capitalization of $8.50 billion, a P/E ratio of 78.54, a price-to-earnings-growth ratio of 1.57 and a beta of 0.55.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.